Logo

Cardiff Oncology Report Results of Onvansertib in P- Ib/II Study for KRAS-Mutated Metastatic Colorectal Cancer

Share this

Cardiff Oncology Report Results of Onvansertib in P- Ib/II Study for KRAS-Mutated Metastatic Colorectal Cancer

Shots:

  • The P-Ib/II study involves assessing of Onvansertib + Folfiri and bevacizumab in 44 patients with 2L treatment of KRAS-mutated mCRC. The company also provided an additional data update from its mCRC clinical program and initial findings from its EAP
  • Out of the 12 P-1b patients- 42% achieved PR & 67% have shown a durable response ranging from 6.1-13.7mos. The RP2D has been established at 15mg/m2 and the P-II segment of the ongoing trial is open to full enrollment of ~26 patients across 6 sites in the US
  • In the EAP- 66% of the initial 9 patients treated have shown tumor shrinkage and remain on treatment to-date with durable responses lasting an avg. of 6 mos.

 ­ Ref: PRNewswire | Image: Cardiff oncology

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions